hapabapa
AbbVie (NYSE:ABBV) shares dropped about 11% after its late-stage trials investigating emraclidine as an oral monotherapy treatment for adults with schizophrenia experiencing acute exacerbation of psychotic symptoms, did not meet their primary endpoint.
The company had acquired emraclidine in its $8.7B acquisition of